Charted
Saturday, Nov. 21, 2026The business of health, by the numbers
Live trackersDeal tracker $50.9B raisedFDA clearances 293 510(k)s in OctoberForm D raises $1.5B in 30 daysNew trials 266 Phase 2/3 in 30 days
Payers & Policy·Hodes Milman

Malpractice firm Hodes Milman targets missed breast cancer diagnoses in California campaign

The Irvine law firm's statewide project focuses on imaging reads, referrals and follow-up, and tells patients to request their reports. It did not disclose case counts, budget or partners.

From a Hodes Milman announcement dated Nov. 20, 2026, and published on PR Newswire Nov. 21, 2026

Hodes Milman, an Irvine, Calif., law firm that represents patients in medical malpractice and personal injury cases, has started a statewide initiative on breast cancer cases it calls diagnostic failures, the firm said Nov. 20.

The effort, named The Missed Diagnosis Project: California, will look at imaging the firm says was misinterpreted, referrals it says were delayed, and follow-up it says was never completed. The firm said it will also coach patients on seeking more testing and second opinions.

Why it matters: The project centers on the handoffs between imaging, ordering clinicians and patients: who reads a scan, who orders the next test, and who explains the result. Those steps are now the focus of a public outreach campaign run by a firm whose business is bringing malpractice claims, and that puts them in front of California health systems, imaging providers, and the insurers that cover them.

What the firm says it will do

Patients will be urged to get copies of their imaging reports, confirm which clinician is responsible for ordering the next test, and keep pressing for evaluation when symptoms continue after a reassuring result, according to the release. The firm said the initiative will also examine racial disparities, as well as obstacles facing rural patients and women younger than 50.

Dan Hodes, the firm's founding and managing partner, framed the project in patient-safety terms. "Breast cancer misdiagnosis is not just a legal issue. It is a patient safety failure," he said.

Hodes said the cases the firm sees most often fall into two groups. In one, a mammogram or ultrasound shows a finding that he said should have led to more workup but was read as benign. In the other, a patient reports a lump or another symptom and, by his account, does not receive imaging or a biopsy quickly enough.

"An abnormal mammogram should trigger action, not confusion," Hodes said. He described the failures as building over several steps rather than a single error, citing examples such as a suspicious finding that is under-called, an MRI that is recommended but never ordered, and a referral that is not made.

What the release leaves out

The announcement gives no figures. It does not say how many breast cancer cases the firm has handled or has pending, whether it has filed or plans to file lawsuits connected to the project, or which providers or health systems are involved in any of the cases it describes.

The release also does not disclose a budget or staffing for the initiative, a timeline, partner organizations, or how the firm will gather information on disparities and rural access. It cites no studies or data on how often breast cancer diagnoses are missed or delayed in California.

The next things to watch are whether the firm publishes findings from the disparities and rural-access work, and whether it attaches case data or specific claims to the project. Providers and payers may also look for any sign that the outreach is producing new patient inquiries about imaging records in the state.

Sara Montes de Oca is the Editor in Chief of Charted. She previously worked as a correspondent and producer in Washington, D.C., covering business, finance, and politics. Drafted with automated tools from the sources listed with this story and checked against them before publishing. How we report.

More Payers & Policy

More
Newsletter

Charted Daily

The day's deals, FDA decisions and policy moves, by the numbers. Free. Sign up now to get the first edition.

No spam. Unsubscribe any time.